REVBW | Revelation Biosciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0112 - 0.0130
52 Week Range	0.0112 - 0.0130
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	106,156
Average Volume	N/A
Shares Outstanding	127,215,982
Market Cap	4,402,413
Sector	Healthcare
Industry	Biotechnology
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	N/A
Forward P/E Ratio	N/A
EPS	-4.77
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	9
Country	USA
Website	REVBW

Revelation Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of immunologic-based therapeutics and diagnostics for the prevention and treatment of disease. The company's lead therapeutic candidate is REVTx-99, an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses, such as SARS-CoV-2 comprising its variants, influenza A and B, parainfluenza, rhinovirus, and RSV, as well as is being developed for other indications comprising allergic rhinitis and chronic nasal congestion. It also develops REVTx-200, an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for immunity; and REVDx-501, a rapid home use diagnostic to detect respiratory viral infection. The company was founded in 2019 and is based in New York, New York.

REVBW's peers: LFLYW, PGYWW, SATLW, REVB, SABSW, SRZNW, JSPRW, ISPOW, DRTSW, ICUCW, SLNAW, ECXWW, MLECW

*Chart delayed

Analyzing fundamentals for REVBW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see REVBW Fundamentals page.

Watching at REVBW technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, but short-term trend is bearish. More technicals details can be found on REVBW Technicals page.